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The serotonin1A (5-HT1A) receptor is an important member of the superfamily of seven-transmembrane domain G-protein-coupled
receptors. We have examined the modulatory role of cholesterol on the ligand binding activity and G-protein coupling of the bovine
hippocampal 5-HT1A receptor by depleting cholesterol from native membranes using methyl-h-cyclodextrin (MhCD). Removal of
cholesterol from bovine hippocampal membranes using varying concentrations of MhCD results in a concentration-dependent reduction in
specific binding of the agonist 8-OH-DPAT to 5-HT1A receptors. This is accompanied by alterations in binding affinity and sites obtained
from analysis of binding data. Importantly, cholesterol depletion affected G-protein-coupling of the receptor as monitored by the GTP-g-S
assay. The concomitant changes in membrane order were reported by changes in fluorescence polarization of membrane probes such as DPH
and TMA-DPH, which are incorporated at different locations (depths) in the membrane. Replenishment of membranes with cholesterol led to
recovery of ligand binding activity as well as membrane order to a considerable extent. Our results provide evidence, for the first time, that
cholesterol is necessary for ligand binding and G-protein coupling of this important neurotransmitter receptor. These results could have
significant implications in understanding the influence of the membrane lipid environment on the activity and signal transduction of other G-
protein-coupled transmembrane receptors.
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Cholesterol is an essential component of eukaryotic
membranes and plays a crucial role in membrane organi-
zation, dynamics, function and sorting [1,2]. It is often
found distributed non-randomly in domains or pools in
biological and model membranes [1–7]. Many of these
domains are believed to be important for the maintenance
of membrane structure and function. In addition, choles-0005-2736/$ - see front matter D 2004 Elsevier B.V. All rights reserved.
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E-mail address: amit@ccmb.res.in (A. Chattopadhyay).terol has been reported to be distributed heterogeneously
among various intracellular membranes. The lowest cho-
lesterol concentration is found in the membranes of the
endoplasmic reticulum, which, interestingly, is the site of
cholesterol biosynthesis [8]. The highest concentration
(f90% of the total cellular cholesterol) is found in the
plasma membrane [9].
A strong asymmetry exists even in the manner choles-
terol is distributed among various organs in the body of
higher eukaryotes. Thus, the central nervous system, which
accounts for only 2% of the body mass, contains f25% of
free cholesterol present in the whole body [10]. Although
the brain is an organ that is highly enriched in cholesterol,
the organization and dynamics of brain cholesterol is still
poorly understood [11]. Brain cholesterol is synthesized in
situ [12] and is developmentally regulated [13]. Cholesterol
organization, traffic, and dynamics in the brain is stringently
controlled since the input of cholesterol into the central
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as there is no available evidence for the transfer of choles-
terol from blood plasma to brain [10]. As a result of this, a
number of neurological diseases share a common etiology
of defective cholesterol metabolism in the brain. In the
Smith–Lemli–Opitz syndrome, for example, the marked
abnormalities in brain development and function leading to
serious neurological and mental dysfunctions have their
origin in the fact that the major input of brain cholesterol
comes from the in situ synthesis, and such synthesis is
defective in this syndrome [14]. The interaction between
cholesterol and other molecular components (such as recep-
tors) in the brain therefore assumes relevance for a compre-
hensive understanding of brain function.
Lipid–protein interactions play a crucial role in main-
taining the structure and function of biological membranes
[15]. A possible role of lipids in a variety of neurological
disorders is well documented [14]. Effects on membrane
function are presumed to be mediated by membrane proteins
and, for this reason, monitoring lipid–protein interactions
assume significance. A large portion of any given trans-
membrane receptor remains in contact with the membrane
lipid environment. This raises the obvious possibility that
the membrane could be an important modulator of receptor
structure and function [16]. A study of such lipid–receptor
interactions is of particular importance because a cell has the
ability of varying the lipid composition of its membrane in
response to a variety of stress and stimuli, thus changing the
environment and the activity of the receptors in its mem-
brane. In view of the importance of cholesterol in relation to
membrane domains, the interaction of cholesterol with
membrane proteins [17] and receptors [16] represents an
important determinant in functional studies of such proteins
and receptors, especially in the nervous system.
Serotonin (5-hydroxytryptamine or 5-HT) is an intrinsi-
cally fluorescent [18], biogenic amine which acts as a
neurotransmitter and is found in a wide variety of sites in
the central and peripheral nervous system [19]. Serotonergic
signaling appears to play a key role in the generation and
modulation of various cognitive and behavioral functions
such as sleep, mood, pain, addiction, locomotion, sexual
activity, depression, anxiety, alcohol abuse, aggression and
learning [20–23]. Disruptions in serotonergic systems have
been implicated in the etiology of mental disorders such as
schizophrenia, migraine, depression, suicidal behavior, in-
fantile autism, eating disorders, and obsessive compulsive
disorder [21,24–26].
Serotonin exerts its diverse actions by binding to distinct
cell surface receptors which have been classified into many
groups [27,28]. Serotonin receptors are members of a
superfamily of seven-transmembrane domain receptors
[29] that couple to GTP-binding regulatory proteins (G-
proteins) [30]. Among the 14 subtypes of serotonin recep-
tors, the G-protein-coupled 5-HT1A receptor subtype is the
most extensively studied for a number of reasons. One of
the main reasons for this is the availability of a selectiveligand (8-OH-DPAT) that allows extensive biochemical,
physiological, and pharmacological characterization of the
receptor [31,32]. The 5-HT1A receptor was the first among
all the serotonin receptors to be cloned and sequenced [33–
35]. The human, rat and mouse 5-HT1A receptors have been
cloned, and their amino acid sequences deduced [34–36].
The cloning of the 5-HT1A receptor gene has shown that it
belongs to the superfamily of G-protein-coupled receptors,
with 50% amino acid homology with the h2-adrenergic
receptor in the transmembrane domain. Furthermore, it
was the first serotonin receptor for which polyclonal anti-
bodies were obtained [34,37–39] allowing their visualiza-
tion at the subcellular level in various regions of the brain.
The 5-HT1A receptor has recently been shown to have a role
in neural development [40] and protection of stressed
neuronal cells undergoing degeneration and apoptosis
[41]. The 5-HT1A receptor antagonists represent a major
class of molecules with potential therapeutic effects in
anxiety- or stress-related disorders [42]. Furthermore, 5-
HT1A receptor levels have been shown to be increased in
schizophrenia [43,44]. The 5-HT1A receptor gene has also
been implicated in Tourette’s syndrome, a common hered-
itary motor and vocal tic disorder [45]. We have earlier
solubilized and partially purified the 5-HT1A receptor from
bovine hippocampus [46,47] and other sources [48] in a
functionally active form. In addition, we have shown
modulation of ligand binding to the bovine hippocampal
5-HT1A receptor by metal ions, guanine nucleotides, alco-
hols, local anesthetics, and covalent modifications of the
disulfides and sulfhydryl groups [49–56].
In this paper, we have explored the modulatory role of
cholesterol on the function (ligand binding) and G-protein
coupling of the bovine hippocampal 5-HT1A receptor by
cholesterol depletion from native membranes using methyl-
h-cyclodextrin (MhCD), which selectively extracts choles-
terol from membranes by including it in a central nonpolar
cavity. The resulting changes in membrane dynamics were
monitored by measurement of fluorescence polarization of
fluorescent probes DPH and TMA-DPH. Our results pro-
vide evidence, for the first time, that cholesterol is necessary
for ligand binding and G-protein coupling of this important
neurotransmitter receptor isolated from its native source.2. Materials and methods
2.1. Materials
BCA, cholesterol, MhCD, DMPC, DPH, EDTA, EGTA,
MgCl2, MnCl2, iodoacetamide, PMSF, serotonin, sucrose,
polyethylenimine, sodium azide, TMA-DPH, and Tris were
obtained from Sigma Chemical Co. (St. Louis, MO). GTP-
g-S was from Roche Applied Science (Mannheim, Ger-
many). BCA reagent kit for protein estimation was from
Pierce (Rockford, IL). Amplex Red cholesterol assay kit
was from Molecular Probes (Eugene, OR). [3H]8-OH-DPAT
Table 1
Effect of cholesterol depletion using MhCD on specific [3H]8-OH-DPAT
binding parametersa
Treatment Kd (nM) Bmax
(fmol/mg)
Control 0.39F0.08 124F13
40 mM MhCD 0.53F0.06 88F5
a Binding parameters were calculated by analyzing saturation binding
isotherms with a range (0.1–7.5 nM) of radiolabeled [3H]8-OH-DPAT
using the LIGAND program. The data represent the meansFS.E. of at least
three independent experiments. See Materials and methods for other details.
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New England Nuclear (Boston, MA). GF/B glass microfiber
filters were from Whatman International (Kent, UK). All
other chemicals used were of the highest purity available.
Water was purified through a Millipore (Bedford, MA)
Milli-Q system and used throughout. Fresh bovine brains
were obtained from a local slaughterhouse within 10 min of
death and the hippocampal region was carefully dissected
out. The hippocampi were immediately flash frozen in
liquid nitrogen and stored at 70 jC till further use.
2.2. Methods
2.2.1. Preparation of native hippocampal membranes
Native hippocampal membranes were prepared as de-
scribed previously [49]. Briefly, bovine hippocampal tissue
(f100 g) was homogenized as 10% (w/v) in a polytron
homogenizer in buffer A (2.5 mM Tris, 0.32 M sucrose, 5
mM EDTA, 5 mM EGTA, 0.02% sodium azide, 0.24 mM
PMSF, 10 mM iodoacetamide, pH 7.4). The homogenate
was centrifuged at 900g for 10 min at 4 jC. The resultant
supernatant was filtered through four layers of cheesecloth
and centrifuged at 50,000g for 20 min at 4 jC. The pellet
obtained was suspended in 10 vol. of buffer B (50 mM Tris,
1 mM EDTA, 0.24 mM PMSF, 10 mM iodoacetamide, pH
7.4) using a hand-held Dounce homogenizer and centri-
fuged at 50,000g for 20 min at 4 jC. This procedure was
repeated until the supernatant was clear. The final pellet
(native membranes) was suspended in a minimum volume
of buffer C (50 mM Tris, pH 7.4), homogenized using a
hand-held Dounce homogenizer, flash frozen in liquid
nitrogen and stored at 70 jC. Protein concentration was
assayed using the BCA assay kit [57].
2.2.2. Radioligand binding assays
Receptor binding assays were carried out as described
earlier with some modifications [49]. Briefly, tubes in dupli-
cate with 0.5 mg protein in a total volume of 1 ml of buffer D
(50 mM Tris, 1 mM EDTA, 10 mM MgCl2, 5 mM MnCl2,
pH 7.4) were incubated with the radiolabeled agonist [3H]8-
OH-DPAT (final concentration in assay tube being 0.29 nM)
for 1 h at room temperature (25 jC). Nonspecific binding
was determined by performing the assay in the presence of 10
AM serotonin. The binding reaction was terminated by rapid
filtration under vacuum in a Brandel cell harvester (Gaithers-
burg, MD) or a Millipore multiport filtration apparatus
through Whatman GF/B 2.5-cm-diameter glass microfiber
filters (1.0 Am pore size) which were presoaked in 0.15%
polyethylenimine for 1 h [58]. Filters were then washed three
times with 3 ml of cold water (4 jC), dried and the retained
radioactivity was measured in a Packard Tri-Carb 1500
liquid scintillation counter using 5 ml of scintillation fluid.
2.2.3. GTP-c-S sensitivity assay
In experiments with GTP-g-S, agonist binding assays
were carried out as described above in the presence ofvarying concentrations of GTP-g-S as described previously
[51]. The concentrations of GTP-g-S leading to 50% inhi-
bition of specific agonist binding (IC50) were calculated by
nonlinear regression fitting of the data to a four-parameter
logistic function [59]:
B ¼ a
1þ ðx=IÞs þ b ð1Þ
where B is the specific binding of the agonist normalized to
control binding (in absence of GTP-g-S), x denotes concen-
tration of GTP-g-S, a is the range ( ymaxymin) of the fitted
curve on the ordinate ( y-axis), I is the IC50 concentration, b
is the background of the fitted curve ( ymin) and S is the slope
factor.
2.2.4. Saturation binding assays
Saturation binding assays were carried out with varying
concentrations (0.1–7.5 nM) of the radiolabeled agonist
([3H]8-OH-DPAT) under conditions as described above.
Nonspecific binding was measured in the presence of 10
AM serotonin. Binding data were analyzed as described
previously [52]. The concentration of the bound radioligand
(RL*) was calculated from the equation:
RL* ¼ 109  B=ðV  SA 2220Þ M ð2Þ
where B is the bound radioactivity in disintegrations per
minute (dpm) (i.e., total dpmnonspecific dpm), V is the
assay volume in milliliters, and SA is the specific activity of
the radioligand. The data could be fitted best to a one-site
ligand binding equation. The dissociation constant (Kd) and
maximum binding sites (Bmax) were calculated by nonlinear
regression analysis of binding data using the HOT module
of the LIGAND program (Biosoft, Cambridge, UK) [60,61].
Data obtained after regression analysis were used to plot
graphs using the GRAFIT program version 3.09b (Erithacus
Software, Surrey, UK). The Bmax values reported in Table 1
have been normalized with respect to the amount of native
membrane protein used.
2.2.5. Cholesterol depletion of native membranes
Native hippocampal membranes were depleted of cho-
lesterol using MhCD as described previously [62,63] with
some modifications. Briefly, membranes resuspended at a
protein concentration of 2 mg/ml were treated with different
Fig. 1. Effect of increasing concentrations of MhCD on lipid composition
of bovine hippocampal membranes. Cholesterol (shaded bars) and
phospholipid (white bars) contents were assayed as described in Materials
and methods. Values are expressed as percentages of the respective lipid
content in native membranes without MhCD treatment. Data for
phospholipid content represent the meansFS.E. of six independent
experiments. Data for cholesterol content represent the meansFS.E. of
three independent experiments. See Materials and methods for other details.
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(25 jC) with constant shaking for 1 h. Membranes were then
spun down at 50,000g for 5 min, washed once with buffer
C and resuspended in the same buffer. Cholesterol was
estimated using the Amplex Red cholesterol assay kit [64].
2.2.6. Cholesterol replenishment of cholesterol-depleted
membranes
Cholesterol-depleted hippocampal membranes were
replenished with cholesterol using a water-soluble choles-
terol–MhCD complex. The complex was prepared by dis-
solving the required amounts of cholesterol and MhCD in a
ratio of 1:10 (mol/mol), respectively, in buffer C by constant
shaking at room temperature (25 jC). Stock solutions
(typically 4:40 mM of cholesterol–MhCD) of this complex
were freshly prepared before each experiment. Cholesterol
replenishment was carried out at a protein concentration of 2
mg/ml by incubating the cholesterol-depleted membranes
with various concentrations of the cholesterol–MhCD com-
plex for 1 h in buffer C at room temperature (25 jC) under
constant shaking. Membranes were then spun down at
50,000g for 5 min, washed once with buffer C and
resuspended in the same buffer. Cholesterol was estimated
using the Amplex Red cholesterol assay kit.
2.2.7. Estimation of inorganic phosphate
Concentration of lipid phosphate was determined subse-
quent to total digestion by perchloric acid [65] using
Na2HPO4 as standard. DMPC was used as an internal
standard to assess lipid digestion. Samples without
perchloric acid digestion produced negligible readings.
2.2.8. Fluorescence polarization measurements
Stock solutions of the fluorescent probes (DPH and
TMA-DPH) were prepared in methanol. Membranes con-
taining 50 nmol of total phospholipids were suspended in
1.5 ml of buffer C and used for fluorescence polarization
experiments. The amount of probe added was such that the
final probe concentration was 1 mol% with respect to the
total phospholipid content. This ensures optimal fluores-
cence intensity with negligible membrane perturbation.
Membranes were vortexed for 1 min after addition of the
probe and kept in the dark for 1 h before measurements.
Background samples were prepared the same way except
that the probe was omitted. The final probe concentration
was 0.33 AM in all cases and the methanol content was
always low (0.03%, v/v). Control experiments showed that
at this concentration of methanol, the ligand binding prop-
erties of the receptor are not altered.
Steady-state fluorescence was measured in a Hitachi F-
4010 spectrofluorometer using 1-cm path length quartz
cuvettes at room temperature (23 jC). Excitation and
emission wavelengths were set at 358 and 430 nm. Excita-
tion and emission slits with nominal bandpasses of 1.5 and
20 nm were used. The excitation slit was kept low to avoid
any photoisomerization of DPH. In addition, fluorescencewas measured with a 30-s interval between successive
openings of the excitation shutter (when the sample was
in the dark in the fluorimeter) to reverse any photoisome-
rization of DPH and TMA-DPH [66]. The optical density of
the samples measured at 358 nm was 0.15F0.01. The
polarization values remained identical even after dilution
of membrane samples, indicating the absence of any scat-
tering artifact [67]. Fluorescence polarization measurements
were performed using a Hitachi polarization accessory.
Polarization values were calculated from the equation [68]:
P ¼ IVV  GIVH
IVV þ GIVH ð5Þ
where IVV and IVH are the measured fluorescence intensities
(after appropriate background subtraction) with the excitation
polarizer vertically oriented and the emission polarizer ver-
tically and horizontally oriented, respectively.G is the grating
correction factor and is equal to IHV/IHH. All experiments
were done with multiple sets of samples and average values
of fluorescence polarization are shown in Figs. 5 and 7.3. Results
3.1. Concentration-dependent cholesterol depletion from
hippocampal membranes by MbCD
The water-soluble compound MhCD has previously
been shown to selectively and efficiently extract cholesterol
from membranes by including it in a central nonpolar cavity
[69–71]. Fig. 1 shows that upon treatment with increasing
concentrations of MhCD, the cholesterol content of bovine
Fig. 2. Effect of (a) increasing concentrations of MhCD and (b) accompanying cholesterol depletion on specific [3H]8-OH-DPAT binding to the 5-HT1A
receptor in bovine hippocampal membranes. Values are expressed as percentage of specific binding for native membranes without MhCD treatment. Data for
the extent of cholesterol depletion with increasing concentrations of MhCD are taken from Fig. 1. The values are the meansFS.E. of at least three independent
experiments. See Materials and methods for other details.
Fig. 3. Saturation binding analysis of specific [3H]8-OH-DPAT binding to
the 5-HT1A receptor in bovine hippocampal membranes treated with
MhCD. Representative plots are shown for specific [3H]8-OH-DPAT
binding with increasing concentrations of free [3H]8-OH-DPAT to control
(- - -o- - -) and 40 mM (—.—) MhCD treated membranes. The curves
are nonlinear regression fits to the experimental data using the LIGAND
program. See Materials and methods and Table 1 for other details.
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Thus, when membranes are treated with 10 mM MhCD,
the cholesterol content is reduced to 75% of control value.
This effect levels off with increasing concentrations of
MhCD, with the cholesterol content of hippocampal mem-
branes being reduced to 12% of the original value when the
membranes are treated with 40 mM MhCD (Fig. 1).
Importantly, the change in phospholipid content under
identical conditions is negligible even when 40 mM MhCD
CD is used and, in all cases, 90% or more of phospholipids
remained in the membrane after MhCD treatment.
3.2. Agonist binding activity is altered upon cholesterol
depletion
Fig. 2 shows the reduction in the specific [3H]8-OH-
DPAT binding with increasing concentrations of MhCD
(Fig. 2a), which results in progressive cholesterol depletion
(Fig. 2b). This shows that removal of cholesterol from
hippocampal membranes results in loss of specific binding
of the agonist [3H]8-OH-DPAT to the 5-HT1A receptor. The
agonist binding, for example, is reduced to 47% of the
original binding observed (in the absence of MhCD treat-
ment) when 40 mM MhCD is used for cholesterol deple-
tion. Although such dependence of ligand binding activity
on membrane cholesterol content has previously been
reported for other receptors [62,72,73], this result represents
the first observation of such dependence for the hippocam-
pal 5-HT1A receptor. As is evident from Fig. 1, the reduction
in cholesterol content upon treating hippocampal mem-
branes with increasing concentrations of MhCD is not
linear. For a comprehensive understanding of the effect of
cholesterol depletion on specific binding of the agonist
[3H]8-OH-DPAT to the 5-HT1A receptor, we plotted the
specific agonist binding data as a function of the extent of
cholesterol depletion with increasing MhCD concentration(see Fig. 2b). It is interesting to note that although the
decrease in specific agonist binding appears to be linear (for
MhCD concentrations>10 mM) when plotted against
MhCD concentration (Fig. 2a), it is not so when viewed
as a function of cholesterol depletion (Fig. 2b). As stated
above, the reason for this difference is that the reduction in
cholesterol content is not linear with the concentrations of
MhCD used.
Saturation binding analysis, shown in Fig. 3 and Table 1,
with the agonist [3H]8-OH-DPAT binding carried out with
native and cholesterol-depleted hippocampal membranes
reveals that the reduction in ligand binding can primarily
be attributed to a reduction in the number of total binding
sites with a marginal reduction in the affinity of ligand
Table 2
Effect of cholesterol depletion using MhCD on specific [3H]8-OH-DPAT
binding sensitivity to GTP-g-Sa
Treatment IC50 (nM)
Control 83F4
40 mM MhCD 206F17
a Sensitivity of specific [3H]8-OH-DPAT binding to GTP-g-S in the
assay was measured by calculating the IC50 for inhibition of [
3H]8-OH-
DPAT binding in the presence of a range of concentrations of GTP-g-S.
Inhibition curves were analyzed using the four-parameter logistic function.
The data represent the means F S.E. of four independent experiments. See
Materials and methods for other details.
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of binding sites (Bmax) when 40 mM MhCD is used for
cholesterol depletion.
3.3. Guanine nucleotide sensitivity of specific agonist
binding in cholesterol-depleted membranes
Most of the seven-transmembrane domain receptors are
coupled to G-proteins [30], and guanine nucleotides are
known to regulate agonist binding. The 5-HT1A receptor is
negatively coupled to the adenylate cyclase system through
pertussis toxin-sensitive G-proteins (Gi/Go) [74]. We previ-
ously showed that the specific binding of the agonist [3H]8-
OH-DPAT to bovine hippocampal 5-HT1A receptors is
sensitive to guanine nucleotides and is inhibited with
increasing concentrations of GTP-g-S, a non-hydrolyzable
GTP analogue [51]. Fig. 4 shows the inhibition of specific
[3H]8-OH-DPAT binding to the 5-HT1A receptor in the
presence of GTP-g-S in a characteristic concentration-de-
pendent manner in control and cholesterol-depleted mem-
branes (using 40 mM MhCD). We have earlier shown that
GTP-g-S induces transition of the receptor from a high
affinity to a low affinity state [51]. Table 2 shows that the
half maximal inhibition concentration (IC50) value for
inhibition of specific [3H]8-OH-DPAT binding by GTP-g-
S is 83 nM for native membranes, similar to what we
reported earlier [51]. The inhibition curve for the cholester-
ol-depleted membranes, however, exhibits a significant
f2.5-fold shift toward higher concentration of GTP-g-S
with an IC50 value of 206 nM. This implies that the agonist
binding to the 5-HT1A receptor in cholesterol-depletedFig. 4. Sensitivity of specific [3H]8-OH-DPAT binding to GTP-g-S in
native and cholesterol-depleted membranes. Values are expressed as
percentage of specific binding for membranes in the absence of GTP-g-S.
Plots show the effect of increasing concentrations of GTP-g-S on the
percentage specific [3H]8-OH-DPAT binding to control (- - -o- - -) and 40
mM MhCD treated (—.—) membranes. The curves are nonlinear
regression fits to the experimental data using the four-parameter logistic
function [59]. The values represent the meansFS.E. of four independent
experiments. See Materials and methods and Table 2 for other details.membranes is less sensitive to GTP-g-S than otherwise
indicating that G-protein coupling of the receptor is drasti-
cally reduced. This points to a possible perturbation of
receptor–G-protein interaction upon cholesterol depletion.
Interestingly, the cholesterol content in membranes has
previously been reported to modulate receptor-independent
function of G-proteins [75,76]. It is therefore possible that a
similar effect could operate here and thus affect the inter-
action between G-proteins and 5-HT1A receptors.
3.4. Changes in hippocampal membrane dynamics due to
cholesterol depletion
A large portion of any given transmembrane protein, the
5-HT1A receptor in this case, remains in contact with the
membrane lipid environment. This raises the obvious pos-
sibility that the overall membrane order and dynamics could
be an important modulator of receptor structure and function
[15,16]. In order to understand the changes in membrane
order induced by cholesterol depletion, we monitored the
steady-state fluorescence polarization of two membrane
probes, DPH and TMA-DPH. DPH and its derivatives
represent popular membrane probes for monitoring organi-
zation and dynamics in membranes [77]. Fluorescence
polarization is correlated to the rotational diffusion [68] of
membrane-embedded probes, which is sensitive to the
packing of fatty acyl chains and cholesterol. Since the
membrane is considered to be a two-dimensional anisotrop-
ic fluid, any possible change in membrane order may not be
uniform and restricted to a unique location in the membrane.
It is therefore important to monitor the change in membrane
order at multiple regions in the membrane to obtain a
comprehensive understanding of any change in membrane
(lipid) dynamics induced by cholesterol depletion. One of us
has previously shown that stress such as heat shock can
induce anisotropic changes in membrane fluidity, i.e., the
change in membrane fluidity was different when monitored
at different regions in adult rat liver cell plasma membranes
[78]. It is worth mentioning here that such depth-dependent
modulation of membrane order induced by alcohols [79]
and local anesthetics [80] has also been reported. It is for
this reason that we employed two fluorescent probes, DPH
and TMA-DPH, to assess any change in membrane order
and dynamics induced by cholesterol depletion. These
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brane. DPH, which is a rod-like molecule, partitions into the
interior of the bilayer. However, its precise orientation in the
membrane interior is not known. TMA-DPH is a derivative
of DPH with a cationic moiety attached to the para position
of one of the phenyl rings [81]. While DPH is known to
partition into the hydrophobic core of the membrane, the
amphipathic TMA-DPH is oriented in the membrane bilayer
with its positive charge localized at the lipid–water interface
[82]. Its DPH moiety is localized atf11 A˚ from the center
of the bilayer and reports the interfacial region of the
membrane [83]. In contrast to this, the average location of
DPH has been shown to be f8 A˚ from the center of the
bilayer [83].
Fig. 5 shows the change in fluorescence polarization of
DPH and TMA-DPH incorporated in hippocampal mem-
branes treated with increasing concentrations of MhCD (Fig.
5a), which results in progressive cholesterol depletion (Fig.
5b). The fluorescence polarization of DPH in hippocampal
membranes (without any MhCD treatment) is found to be
0.334. This is very close to the value found in the detergent-
resistant fraction of liposomes composed of bovine phos-
phatidylcholine, sphingomyelin, cerebroside, along with
cholesterol [84]. The corresponding value of fluorescence
polarization for TMA-DPH is 0.363. The higher polarization
of TMA-DPH compared to DPH is indicative of the shal-
lower location of TMA-DPH in the membrane, as has been
observed earlier for anthroyloxy-labeled fluorescent mem-
brane probes [85]. The fluorescence polarization of both the
probes shows a continuous decrease with increasing con-
centrations of MhCD. Interestingly, the fluorescence polar-
ization of both the probes shows an almost linear dependence
when plotted against increasing extents of cholesterol deple-
tion (see Fig. 5b). More importantly, the percentage change
in fluorescence polarization upon cholesterol depletion isFig. 5. Effect of (a) increasing concentrations of MhCD and (b) accompanying
polarization of membrane probes DPH (o) and TMA-DPH (.). Fluorescence pol
phospholipid at a probe to phospholipid ratio of 1:100 (mol/mol) at room tempe
concentration of MhCD are taken from Fig. 1. The values represent the meansFS
details.higher for DPH (16%) compared to TMA-DPH (9%) when
40 mM MhCD is used for cholesterol depletion. The
polarization values remained identical even after dilution
of membrane samples indicating the absence of any scatter-
ing artifact [67]. Thus, the asymmetric reduction in mem-
brane order in different regions upon cholesterol depletion is
accompanied with a reduction in the agonist binding activity
of the 5-HT1A receptor.
3.5. Cholesterol replenishment restores agonist binding
activity of the 5-HT1A receptor and membrane order in
hippocampal membranes
In order to check the reversibility of the changes induced
by cholesterol depletion, cholesterol replenishment of de-
pleted membranes (achieved using 40 mM MhCD) was
carried out by incubating the depleted membranes with
cholesterol–MhCD complex as described in Materials and
methods. As shown in Fig. 6a, this procedure is able to
replenish bulk of the cholesterol to the depleted membranes
as shown by the cholesterol content of the replenished
membranes. Interestingly, the efficiency of the cholesterol
replenishment process (and also effect on ligand binding
activity, see Fig. 6b) appears to be influenced by the
concentration of the cholesterol–MhCD complex used even
while maintaining the same ratio (1:10, mol/mol) of cho-
lesterol to MhCD. The optimum efficiency of loading
cholesterol back to depleted membranes is found with 1
mM cholesterol complexed with 10 mM MhCD. Use of
higher concentrations of the complex with the same molar
ratio failed to increase the cholesterol replenishment effi-
ciency (not shown). Thus,f72% of the original cholesterol
content could be loaded back when 1 mM cholesterol
complexed with 10 mM MhCD is used. The corresponding
recovery in ligand binding activity is shown in Fig. 6b withcholesterol depletion in bovine hippocampal membranes on fluorescence
arization experiments were carried out with membranes containing 50 nmol
rature (23 jC). Data for the extent of cholesterol depletion with increasing
.E. of three independent experiments. See Materials and methods for other
Fig. 6. Cholesterol replenishment into bovine hippocampal membranes treated with MhCD and its correlation with (a) cholesterol content and (b) specific
[3H]8-OH-DPAT binding activity of the hippocampal 5-HT1A receptor. Cholesterol depletion was carried out using 40 mM MhCD as described in Materials
and methods. Panel (a) shows the final cholesterol content when cholesterol-depleted membranes were treated with cholesterol–MhCD complex at a final
concentration of 0.5:5 mM and 1:10 mM (mol/mol of cholesterol –MhCD). Values are expressed as percentage of cholesterol content in native membrane
without any treatment. Panel (b) shows the accompanying effect of cholesterol replenishment on the specific [3H]8-OH-DPAT binding to membranes. Values
are expressed as percentage of specific radiolabeled agonist binding in native membranes without any treatment. The data represent meansFS.E. of three
independent experiments. See Materials and methods for other details.
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membranes.
Fig. 7 shows the increase in fluorescence polarization of
DPH and TMA-DPH following cholesterol replenishment
with increasing concentrations of cholesterol–MhCD com-
plex (Fig. 7a) which results in progressive increase in
cholesterol content (Fig. 7b). This increase in fluorescence
polarization again displays all characteristic features as
were observed with data shown in Fig. 5, i.e., the linearity
with increasing cholesterol content (see Fig. 7b) and DPH
fluorescence polarization being more sensitive to mem-Fig. 7. Effect of cholesterol replenishment on the fluorescence polarization of m
experiments were carried out with membranes containing 50 nmol phospholipid a
jC). Panel (a) shows the effect of increasing concentrations of MhCD–chole
membranes. Panel (b) shows the effect of increasing extent of cholesterol replenis
without MhCD treatment) on fluorescence polarization in membranes. Data for
fluorescence polarization of DPH (5) and TMA-DPH (n) for control membranes
are taken from Fig. 5. The values are the meansFS.E. of three independent expebrane cholesterol content compared to TMA-DPH. Impor-
tantly, the polarization values obtained with membranes
replenished with 1 mM cholesterol complexed with 10
mM MhCD are 95–98% of the polarization values
obtained in control membranes for DPH and TMA-DPH.
The recovery of fluorescence polarization values upon
cholesterol replenishment to nearly those found with con-
trol membranes further ensures, over and above the cho-
lesterol content analysis, that membrane physical properties
(such as membrane order) are restored to a large extent. As
stated earlier, cholesterol is often found non-randomlyembrane probes DPH (o) and TMA-DPH (.). Fluorescence polarization
t a probe to phospholipid ratio of 1:100 (mol/mol) at room temperature (23
sterol complex on fluorescence polarization of DPH and TMA-DPH in
hment (expressed as percentage of cholesterol content in native membranes
the extent of cholesterol replenishment are taken from Fig. 6a. Data for
(considered as 100% cholesterol content) are provided for comparison and
riments. See Materials and methods for other details.
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depletion by MhCD is reported to be asymmetric with
respect to the amount extracted from these pools [86,87].
Replenishment of cholesterol therefore may not bring the
membrane back to its original state as far as distribution of
cholesterol in different pools is concerned. Thus, although
the overall level of cholesterol after replenishment may be
nearly equal to the original level of cholesterol, it does not
necessarily guarantee recovery of all functional attributes
(ligand binding) since it may require a much more strin-
gent criterion such as comparable distribution of choles-
terol among various pools and proper conformation of
membrane receptors which are influenced by neighboring
lipids molecules.4. Discussion
The 5-HT1A receptor belongs to the family of G-protein-
coupled receptors. These receptors constitute a superfamily
of proteins whose function is to transmit information across
a cell membrane from the extracellular environment to the
interior of the cell, thus providing a mechanism of commu-
nication between the exterior and the interior of the cell
[29]. G-protein-coupled receptors represent the single larg-
est family of cell surface receptors involved in signal
transduction. This receptor superfamily includes over 2000
receptors which respond to a variety of molecules such as
neurotransmitters, hormones, taste and odorant molecules,
and even photons, thus mediating a multitude of functions.
According to current estimates, about 1% of the mammalian
genome codes for this type of receptors [88]. These trans-
membrane receptors act as key players in diverse physio-
logical processes such as neurotransmission, cellular
metabolism, secretion, cellular differentiation and growth,
and inflammatory and immune responses. G-protein-cou-
pled receptors therefore represent major targets for the
development of novel drug candidates in all clinical areas
[89]. It is estimated that 30% of clinically prescribed drugs
function as either agonists or antagonists of G-protein-
coupled receptors, which points to their immense therapeu-
tic potential [90].
The membrane organization of G-protein-coupled recep-
tors assumes significance in the light of their role in health
and disease. Recent evidence has indicated that the receptors
and G-proteins are less dynamic than previously appreciat-
ed. A spatiotemporally organized system rather than a freely
diffusible system has been suggested to be responsible for
rapid and specific propagation of extracellular stimuli to
intracellular signaling molecules [88,91]. Moreover, the
specificity of signaling in intact cells appears to be signif-
icantly greater than that observed in reconstituted systems.
Based on this and other types of evidence, it has been
proposed that the G-protein-coupled receptors are not uni-
formly present on the plasma membrane but are concentrat-
ed in specific membrane microdomains [88,91–93]. It hasbeen shown that some of these domains are enriched in
cholesterol. For example, it has recently been reported
that 5-HT2A receptors in smooth muscle cells are localized
in membrane microdomains (caveolae) and serotonergic
signaling in these cells depends on cholesterol content
[94]. Localization of G-protein-coupled receptors into
domains has given rise to new challenges and complex-
ities in receptor signaling since signaling has to be
understood in context of the three-dimensional organiza-
tion of various signaling components, which include
receptors and G-proteins [92].
We show here that removal of cholesterol from bovine
hippocampal membranes using varying concentrations of
MhCD results in a concentration-dependent decrease in
specific binding of the agonist 8-OH-DPAT to 5-HT1A
receptors. This is accompanied by alterations in binding
affinity and sites obtained from analysis of binding data.
Importantly, cholesterol depletion affected G-protein-cou-
pling of the receptor as monitored by the GTP-g-S assay.
The concomitant changes in membrane order were reported
by changes in fluorescence polarization of membrane
probes, such as DPH and TMA-DPH, which are incorpo-
rated at different locations (depths) in the membrane.
Replenishment of membranes with cholesterol led to recov-
ery of ligand binding activity as well as membrane order to a
considerable extent. The clinical significance of membrane
cholesterol levels resulting in receptor dysfunction has been
aptly exemplified in the case of cholecystokinin (CCK)
receptors [95,96]. Thus, agonist binding is reduced and G-
protein coupling affected for CCK receptors isolated from
muscle tissues in human gallbladders with cholesterol
stones. These effects are reversed upon treatment with
cholesterol-free liposomes.
Since cholesterol is an essential component in eukaryotic
cell membranes [97], one would be tempted to consider that
the function of several G-protein-coupled receptors would
be affected in a similar fashion upon cholesterol depletion.
A careful study of the existing literature reveals this to be
not true and the real effect observed depends on the specific
receptor type and the membrane environment the receptor is
present in. For instance, the 5-HT1A receptor belongs to the
subset of G-protein-coupled receptors that bind to biogenic
amines. This family also includes the h2-adrenoceptor and
rhodopsin. The 5-HT1A receptor showsf50% homology in
the transmembrane region to the h2-adrenoceptor whereas
most structural simulations of the G-protein-coupled recep-
tors, including the 5-HT1A receptor [98], make use of the
rhodopsin crystal structure as a template. This highlights the
similarities between these proteins. Yet, work with purified
and reconstituted receptor preparations has revealed that
while the h2-adrenoceptor requires membrane cholesterol to
promote efficient ligand binding, G-protein coupling and
downstream signal transduction [99,100], analogous func-
tions of rhodopsin, are inhibited in the presence of mem-
brane cholesterol [101–103]. As the above example shows,
even among the members of the G-protein-coupled receptor
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literature already shows a lack of consensus in the manner
in which cholesterol modulates receptor function.
Our results show that manipulations of membrane cho-
lesterol content can induce significant changes in the
activity and G-protein coupling of the 5-HT1A receptor.
Whether such manipulations in membrane cholesterol con-
tent could be induced in vivo represents a challenging
question. The turnover of brain cholesterol is very low,
with a half-life of f6 months [10]. As a result of this, the
cerebrospinal fluid levels of cholesterol are f40–50-fold
lower than the plasma cholesterol [104]. Due to the pres-
ence of the blood brain barrier, alterations in serum levels of
cholesterol are believed not to affect the total cholesterol
level in the central nervous system. However, under such
conditions, the neuronal plasma membrane fractions have
not been studied adequately. In addition, regions in the
central nervous system (such as the hypothalamic area) that
are somewhat weakly protected by the blood brain barrier
may be sensitive to plasma cholesterol fluctuations. Inter-
estingly, a recent report has suggested that chronic in vivo
administration of cholesterol-lowering drugs like statins
specifically reduces brain cholesterol levels, leaving the
serum cholesterol levels unaffected [105]. More impor-
tantly, it has been shown that treating humans with such
cholesterol-lowering drugs significantly decreases the inci-
dence of Alzheimer’s disease [106,107]. It is possible that
the more severe deficiency in cholesterol levels in the brain
occurs on account of the lower turnover of cholesterol in
this tissue. Interestingly, low serum cholesterol concentra-
tion has been correlated with an increase in the prevalence
of suicide in humans [108] and is partly attributed to an
altered serotonin metabolism [109]. Furthermore, a recent
report describes the attenuation of 5-HT1A receptor antag-
onist binding and signaling in brains of suicide victims
[110]. In light of our present results on the requirement of
membrane cholesterol to influence the 5-HT1A receptor
function, its role in the etiology of psychological disorders
that are correlated with an altered cholesterol metabolism
clearly needs to be investigated further.
In summary, our results show that cholesterol has an
important role in regulation of ligand binding activity and
G-protein coupling of the 5-HT1A receptor. These results are
relevant in understanding the role of the membrane lipid
environment on the activity and signal transduction of other
G-protein-coupled transmembrane receptors.Acknowledgements
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